Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Sleep architecture in ziprasidone-treated bipolar depression: a pilot study.

Baskaran A, Summers D, Willing SL, Jokic R, Milev R.

Ther Adv Psychopharmacol. 2013 Jun;3(3):139-49. doi: 10.1177/2045125312467348.

2.

Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial.

Lazowski LK, Townsend B, Hawken ER, Jokic R, du Toit R, Milev R.

BMC Psychiatry. 2014 Jul 17;14:202. doi: 10.1186/1471-244X-14-202.

3.

Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression.

Gedge L, Lazowski L, Murray D, Jokic R, Milev R.

Neuropsychiatr Dis Treat. 2010 Sep 7;6:501-8.

4.

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B.

J Clin Psychiatry. 2011 Oct;72(10):1413-22. doi: 10.4088/JCP.09m05934.

PMID:
21672493
5.

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.

Potkin SG, Keck PE Jr, Segal S, Ice K, English P.

J Clin Psychopharmacol. 2005 Aug;25(4):301-10.

PMID:
16012271
6.

Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?

Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R.

J Clin Psychopharmacol. 2012 Aug;32(4):470-8. doi: 10.1097/JCP.0b013e31825ccde5.

PMID:
22722504
7.

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.

Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; Ziprasidone in Mania Study Group.

Am J Psychiatry. 2003 Apr;160(4):741-8.

PMID:
12668364
8.
9.

Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.

Hirschfeld RM, Weisler RH, Raines SR, Macfadden W; BOLDER Study Group.

J Clin Psychiatry. 2006 Mar;67(3):355-62.

PMID:
16649820
10.

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.

Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC.

BMC Psychiatry. 2013 May 14;13:138. doi: 10.1186/1471-244X-13-138.

11.

A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.

Patkar AA, Pae CU, Vöhringer PA, Mauer S, Narasimhan M, Dalley S, Loebel A, Masand PS, Ghaemi SN.

J Clin Psychopharmacol. 2015 Jun;35(3):319-23. doi: 10.1097/JCP.0000000000000323.

PMID:
25882763
12.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
13.

Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study.

Wang M, Tong JH, Huang DS, Zhu G, Liang GM, Du H.

Psychopharmacology (Berl). 2014 Jul;231(14):2811-8. doi: 10.1007/s00213-014-3453-1. Epub 2014 Jan 31.

PMID:
24481570
14.
15.

Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.

Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, Earley W, Datto C.

Am J Geriatr Psychiatry. 2013 Aug;21(8):769-84. doi: 10.1016/j.jagp.2013.01.010. Epub 2013 Feb 6.

PMID:
23567397
16.

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.

Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J.

Am J Psychiatry. 2005 Jul;162(7):1351-60.

PMID:
15994719
17.
18.
20.

Supplemental Content

Support Center